Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide

E-ISSN： 1873-4286|10|27|3331-3348

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.27, 2004-01, pp. : 3331-3348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular Endothelial Growth Factor and Diabetic Retinopathy: Role of Oxidative Stress

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 511-524

Bentham Science Publishers

Access to resources Recommend Favorite

Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents

Current Cancer Drug Targets, Vol. 7, Iss. 5, 2007-08 ,pp. : 475-483

Bentham Science Publishers

Access to resources Recommend Favorite

Vasoactive substances - Nitric oxide and endothelial dysfunction in atherosclerosis

By Russo G. Leopold J.A. Loscalzo J.

General Pharmacology, Vol. 38, Iss. 5, 2002-05 ,pp. : 259-269

Elsevier

Access to resources Recommend Favorite

The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease

Current Pharmaceutical Design, Vol. 10, Iss. 27, 2004-10 ,pp. : 3385-3394

Bentham Science Publishers

Access to resources Recommend Favorite

Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model

By Ayalasomayajula S.P. Kompella U.B.

European Journal of Pharmacology, Vol. 458, Iss. 3, 2003-01 ,pp. : 283-289

Elsevier

Access to resources Recommend Favorite